A PD-L1 Aptamer Selected by Loss-Gain Cell-SELEX Conjugated with Paclitaxel for Treating Triple-Negative Breast Cancer

BACKGROUND: The clinical challenges of triple-negative breast cancer (TNBC) includes the lack of targeted therapy and chemoresistance. TNBC has relatively high PD-L1 expression, and PD-L1 antibody in combination with nab-paclitaxel has been approved by FDA for TNBC treatment. Aptamers, also termed c...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Xiaoqiu, Li, Fangfei, Li, Yongshu, Yu, Yuanyuan, Liang, Chao, Zhang, Baoting, Zhao, Chuanzong, Lu, Aiping, Zhang, Ge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2020
Materias:
Lab/In Vitro Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331476/
https://www.ncbi.nlm.nih.gov/pubmed/32574155
http://dx.doi.org/10.12659/MSM.925583

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331476/
https://www.ncbi.nlm.nih.gov/pubmed/32574155
http://dx.doi.org/10.12659/MSM.925583

Ejemplares similares